Biotechnology · Nasdaq

GILDGilead Sciences, Inc.

Last close
$168.08 +0.1%
52-week range
$116.88 to $176.58
Market cap
$208B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$29.4B
+2% vs FY24
Net income
$8.51B
+1,673% vs FY24
Free cash flow
$9.46B
-8% vs FY24
Net cash
-$17.3B
Cash $7.63B, debt $24.9B

Stock price

+131% since Dec 2016

Valuation vs its own 10 years

Above its 10-year median on all 2 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
n/a
n/a: No earnings
Median 18.8x, range 7.2x to 956x
Price / sales
6.7x
2.7x6.7x
Highest point in its range, above its median of 3.7x
EV / EBITDA
n/a
n/a: Not meaningful (negative or missing)
Median 13.5x, range 5.9x to 103x
Price / free cash flow
15.1x
5.8x17.1x
92nd percentile, above its median of 11.1x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
n/aNo earnings
Earnings yield
-1.9%
Price / sales
6.7x
Price / book
16.0x
Price / operating cash flow
14.4x
EV / EBITDA
n/aNot reported
EV / sales
7.4x
Free cash flow yield
6.6%

Profitability

Gross margin
79.9%
Operating margin
-7.6%
Net margin
-12.5%
Return on equity
-29.6%
Return on capital
-4.8%

Growth per year

Revenue, 3 years
+2.6%
Revenue, 5 years
+3.6%
Revenue, 9 years
-0.4%
EPS, 3 years
+23.0%

Balance sheet

Cash and investments
$6.44B
Total debt
$26.2B
Net cash
-$19.8B
Debt / equity
2.01x
Current ratio
1.38x

Shares and dividend

Shares outstanding
1.24B
Share count, 5 years
-0.6%
Beta, 1 year
0.37
Dividend yield
1.9%
Dividend per share, TTM
$3.25
Payout ratio
n/aNot meaningful

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $8.30B
RevenueNet income
Gross profitLatest quarter $6.73B
EBITDALatest quarter $3.59B
Margins81 / 42 / 29%
GrossOperatingNet
Earnings per shareLatest quarter $1.94
Cash flowLatest quarter $5.04B
OperatingCapexFree
Cash vs debtLatest quarter $6.44B
Cash and investmentsTotal debt
P/E historyNow n/a
P/E, median 18.8x dashed
P/S historyNow 6.7x
P/S, median 3.7x dashed

Where the revenue comes from

HIV Products Biktarvy went from 38% to 49% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

HIV Products BiktarvyOncology ProductLiver DiseaseCell Therapy Products Total Cell Therapy Product SalesHIV Products GenvoyaOther Products YescartaOther
FY22
38%10%9%11%
$27.3B
FY23
44%11%11%
$27.1B
FY24
47%11%10%
$28.8B
FY25
49%11%11%13%
$29.4B
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
HIV Products Biktarvy$14.3B48.7%+7%
Oncology Product$3.24B11.0%-2%
Liver Disease$3.22B10.9%n/a
Cell Therapy Products Total Cell Therapy Product Sales$1.84B6.2%-7%
HIV Products Genvoya$1.50B5.1%-15%
Other Products Yescarta$1.50B5.1%-5%
Other$3.84B13.0%+32%

Biotechnology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
ONC BeOne Medicines Ltd. $619B +33% 17.8%689x93.6x Not enough history
ABBV AbbVie Inc. $521B +11% 32.2%50.8x7.9x 72nd percentile
AMGN Amgen Inc $252B +8% 32.4%27.0x6.5x 78th percentile
GILD Gilead Sciences, Inc. $208B +7% -7.6%No earnings6.7x No earnings
VRTX Vertex Pharmaceuticals Inc / Ma $137B +10% 33.2%34.7x10.5x 71st percentile
MRNA Moderna, Inc. $90.4B +13% -116%No earnings35.8x No earnings

The company

Sector
Health Care
Industry
Biotechnology
CEO
Daniel O'Day
Employees
17,000 (as of 2026)
Founded
1987
Headquarters
Foster City, CA
Fiscal year ends
December
Website
gilead.com

What it does

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about GILD.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 1,961 active funds. Crowd level: quiet.

Open the Smart money tab